Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.34 |
| ▸ | CAD | P27708 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL112014 | 1.00 | CPB2 (0.44) | CPB2ALOX15CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL112015 | 1.00 | CPB2 (0.44) | CPB2ALOX15CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1176235 | 0.86 | ALOX15 (0.48) | CPB2ALOX15CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14608482 | 0.86 | CPB2 (0.49) | CPB2ALOX15CYP2D6CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL7001552 | 0.84 | ALOX15 (0.46) | CPB2ALOX15CYP2D6CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL1176232 | 0.84 | ALOX15 (0.46) | CPB2ALOX15CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL110467 | 0.83 | NOD1 (0.37) | CPB2ALDH1A1NOD1ANPEPENPEP | |
| SCHEMBL110469 | 0.83 | NOD1 (0.37) | CPB2ALDH1A1NOD1ANPEPENPEP | |
| SCHEMBL110468 | 0.83 | NOD1 (0.37) | CPB2ALDH1A1NOD1ANPEPENPEP | |
| SCHEMBL111398 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2309983-B1 | PHARMACEUTICAL FORM COMPRISING TETRAHYDROBIOPTERIN | ORPHA SWISS GMBH (CH) | 2019-04-24 | — | — | EP | claimed |
| CN-102802605-A | Stable lipid formulations of apoptosis promoters | ABBOTT LAB | 2012-11-28 | — | — | CN | claimed |
| EP-2424499-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | claimed |
| US-20110144117-A1 | Pharmaceutical Dosage Form Containing Tetrahydrobiopterin | ORPHA SWISS GMBH (CH) | 2011-06-16 | — | — | US | claimed |
| WO-2010127193-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | claimed |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBVIE INC. | 2010-11-04 | — | — | US | claimed |
| CN-112334167-A | Hydrogel compositions comprising crosslinked polymers | 克罗马药品有限责任公司 | 2021-02-05 | — | — | CN | disclosed |
| CN-112334166-A | Hydrogel compositions comprising crosslinked polymers | 克罗马药品有限责任公司 | 2021-02-05 | — | — | CN | disclosed |
| CN-102655858-B | ABT-263 capsule | ABBVIE (US) | 2015-11-25 | — | — | CN | disclosed |
| CN-102802605-B | Stable lipid formulations of apoptosis promoters | ABBVIE (US) | 2015-08-12 | — | — | CN | disclosed |
| US-8927009-B2 | ABT-263 capsule | ABBVIE INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8728516-B2 | Stabilized lipid formulation of apoptosis promoter | ABBVIE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8513243-B2 | ABT-263 crystalline forms | ABBVIE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-5720944-A | POLYGLYCOL MONOTHIO(GLYCOLATE OR LACTATE) AS REDUCING AGENTS | KAO CORPORATION (JP) | 1998-02-24 | — | — | US | disclosed |
| US-5720945-A | 1,3-butanediol thioglycollate isomer mixture and permanent waving composition comprising same | KAO CORPORATION (JP) | 1998-02-24 | — | — | US | disclosed |
| EP-0734715-A2 | 1,3-Butanediol thioglycolate isomer mixture and permanent waving composition comprising same | Kao Corporation (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0734716-A2 | Composition for permanent waving of human hair | Kao Corporation (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0297621-B1 | Cyclic amino-thioacetal amides, a process for the preparation thereof and pharmaceutical compositions containing them | BOEHRINGER MANNHEIM ITALIA (IT) | 1994-09-21 | — | — | EP | disclosed |
| US-4988701-A | Cyclic amino-thioacetal amides, a process for the preparation thereof and pharmaceutical compositions | BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1991-01-29 | — | — | US | disclosed |
| EP-0297621-A2 | Cyclic amino-thioacetal amides, a process for the preparation thereof and pharmaceutical compositions containing them | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1989-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | BCL2, BAX, BCOR | CPB2 4292/4885ALOX15 615/4885CYP2D6 1190/4885 |
| US-20110144117-A1 | Pharmaceutical Dosage Form Containing Tetrahydrobiopterin | QDPR, MTHFD2, DHODH | CPB2 765/4885ALOX15 465/4885CYP2D6 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.